世界の短期腸症候群市場(医薬品クラス- GLP-2、成長ホルモン、グルタミン)-グローバル産業分析、規模、シェア、量、成長、動向及び予測2016-2024

◆英語タイトル:Short Bowel Syndrome Market (Drug Class - GLP-2, Growth Hormone, and Glutamine) - Global Industry Analysis, Size, Share, Volume, Growth, Trends, and Forecast 2016 - 2024
◆商品コード:TMR70221072
◆発行会社(リサーチ会社):Transparency Market Research
◆発行日:2017年1月24日
◆ページ数:124
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:産業未分類
◆販売価格オプション(消費税別)
Single UserUSD5,795 ⇒換算¥637,450見積依頼/購入/質問フォーム
Multi UserUSD8,795 ⇒換算¥967,450見積依頼/購入/質問フォーム
Corporate LicenseUSD11,795 ⇒換算¥1,297,450見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTransparency Market Research社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。Transparency Market Research社の概要及び新刊レポートはこちらでご確認いただけます。

本調査レポートでは、世界の短期腸症候群市場について調査・分析し、世界の短期腸症候群市場規模、市場シェア、成長、市場動向、市場予測、セグメント別市場規模・分析、地域別市場規模・分析、関連企業動向などを含め、以下の構成でお届けいたします。
【レポートの概要】

Short Bowel Syndrome Market: Overview
Short bowel syndrome (SBS) is the malabsorption of nutrients caused by removal of small intestine and in rare cases, the dysfunction of particular segments of the bowel. Nutrients are absorbed by the small intestine with the help of villi that are connected to blood capillaries. The condition is extremely rare and affected people exhibit symptoms such as abdominal pain, diarrhea, dehydration, weight loss, fatigue, malnutrition and weakness. Deficiencies of major nutrients such as vitamins and minerals can cause a host of other illnesses and disorders such as swelling, easy, bruising, difficulty in blood clotting, reduced immunological response, anemia, hyperkeratosis, bone and joint pain due to osteoporosis. The condition is also known as Small Intestine Insufficiency.

Surgical removal of small intestine can occur mainly under three conditions; necrotizing enterocolitis that is the death of intestinal wall due to reduced blood supply, malformation of intestine and Crohn’s Disease which is a condition that causes inflammation of the bowel wall and attacks all parts of the digestive tract, from mouth to anus, for unknown reasons. Crohn’s Disease is a fairly uncommon disease that affects approximately 4.5 million people across the world. According to data from CDC, NIH and other organizations, incidence of Crohn’s Disease is estimated to vary between 0.1–16/100,000 persons worldwide as of 2014. Extrapolation of abdominal surgery procedures indicate that approximately 3 million small bowel resection surgeries may be performed each year that include duodenectomies, Jejunectomies and ileectomies.

Short Bowel Syndrome Market: Diagnostic and Treatment Landscape

There are several methods for testing and diagnosing short bowel syndrome based on the symptoms and body functions. Blood chemistry tests such as albumin level test indicates if the body has reduced nutrient contents. Other tests include complete blood count, fecal fat test, small intestine x-ray and vitamin level blood tests. These laboratory tests are easily available and can be performed as an outpatient setting. High calorie diet, vitamin supplements, carbohydrates, protein and fat enriched foods are the essential treatment options for patients suffering from SBS. Under duress, a patient can also be treated with parenteral nutrition.

Medications for this disorder include drugs that slow bowel movement as a result of which, food remains in contact with the intestines for a longer time giving a chance for greater absorption of nutrients. In 2012, Gattex (teduglutide) has been one of the latest drugs to be approved by the FDA for SBS. Octreotide Acetate Injection is also considered as an off-label treatment drug for SBS. Sandostatin (Octreotide Acetate Injection) and somatostatin are manufactured by a number of companies such as TEVA pharmaceuticals, Wockhardt, Sandoz, Bioniche Pharma, Sun Pharmaceuticals, Sandostatin LAR and Novartis among several others.

Short Bowel Syndrome Market: Region-wise Insight

Geographically market is dominated by developed economic countries due to government intervention and presence of advanced healthcare facilities have essentially contributed in generating revenues. Currently in United States approximately 10,000 – 20,000 people in the United States suffers from short bowel syndrome. Increasing awareness and inclination of companies in gaining access to European marketing approval has significantly contributed in escalating market for SBS in European countries.

The market for SBS in Asia Pacific and Rest of the World is currently a growing stage. Owing to large population base and lack of hygienic food and burgeoning intestinal and digestion disorders is expected to grow the market in forthcoming years.

Short Bowel Syndrome Market: Competition Snapshot

Some of the leading players operating in the global Short bowel syndrome market comprises Takeda Pharmaceutical Company, NPS Pharmaceuticals, TEVA pharmaceuticals, Novartis International AG, XTEND and others.

In March 2013 the United States based NPS Pharmaceuticals reacquired worldwide marketing rights for short bowel syndrome drug Revestive from Takeda Pharmaceutical Company Limited. Additionally in September 2012, Revestive has already got European marketing authorization for treating adults with SBS. In December 2012 Teduglutide, a new drug got FDA approval for treating patients suffering with SBS and are dependent on parenteral nutrition or intravenous therapy.

The report offers a comprehensive evaluation of the market. It does so via in-depth insights, understanding market evolution by tracking historical developments, and analyzing the present scenario and future projections based on optimistic and likely scenarios. Each research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology developments, types, applications, and the competitive landscape.

The study is a source of reliable data on:

Key market segments and sub-segments
Evolving market trends and dynamics
Changing supply and demand scenarios
Quantifying market opportunities through market sizing and market forecasting
Tracking current trends/opportunities/challenges
Competitive insights
Opportunity mapping in terms of technological break throughs
The regional analysis covers:

North America (U.S. and Canada)
Latin America (Mexico, Brazil, Peru, Chile, and others)
Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, Luxembourg)
Eastern Europe (Poland, Russia)
Asia Pacific (China, India, Japan, ASEAN, Australia and New Zealand)
Middle East and Africa (GCC, Southern Africa, North Africa)

TMR estimates the market size of various sectors using a combination of available data on the number and revenue of companies within each sub-sector and tiers of companies. The basic components used to determine market size and forecast for a specific product area are not only limited to supply-side data, but are also related to demand, industry trends, and the economic outlook. All the above data points are utilized to generate a statistical model targeting the sector marketplace. More than 300 TMR analysts across the world integrate these elements into a framework to determine the subsector market size for a base year and then forecast growth within each market.

TMR regularly interviews technology and business professionals as an ongoing effort to track the latest developments within each sector. These continuous surveys are stratified by company size and industry segment and weighted to reflect the global market place. All data are collected on an ongoing effort through a structured questionnaire rolled over the web or conducted via telephones. This provides the TMR team opportunities to request for detailed question sets, complex skip patterns, and real-time calculations, which assists respondents in answering questions involving numbers and percentages. Respondents, who are interviewed as experts, are screened and qualified based on certain criteria in addition to their decision-making authority and the scope of activity within their organizations.

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

【レポートの目次】

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Short Bowel Syndrome

4. Market Overview
4.1. Introduction
4.1.1. Drug Class Definition
4.1.2. Industry Evolution / Developments
4.2. Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunity
4.3. Global Short Bowel Syndrome Analysis and Forecasts, 2014–2024
4.3.3. Market Revenue Projections (US$ Mn)
4.4. Porter’s Five Force Analysis
4.5. Value Chain Analysis
4.6. Market Outlook
4.7. Disease Overview
4.8. Disease Epidemiology
4.9. Patent Information
4.10. Overview of Clinical Trials
4.11. Qualitative Analysis of GLP-2 product
4.12. Mode of action of SBS drugs
4.13. Regulatory Scenario

5. Global Short Bowel Syndrome Analysis and Forecasts, By Drug Class
5.1. Introduction & Definition
5.2. Key Findings / Developments
5.3. Key Trends
5.4. Market Value (US$ Mn) Forecast By Drug Class, 2014–2024
5.4.1. GLP-2
5.4.2. Growth Hormone
5.4.3. Glutamine
5.4.4. Others
5.5. Market Attractiveness by Drug Class

6. Global Short Bowel Syndrome Analysis and Forecasts, By Region
6.1. Key Findings
6.2. Market Value (US$ Mn) Forecast By Region
6.2.1. North America
6.2.2. Europe
6.2.3. Rest of the World
6.3. Market Attractiveness by Country/Region

7. North America Short Bowel Syndrome Analysis and Forecast
7.1. Introduction
7.1.1. Key Findings
7.1.2. Key Trends
7.2. Market Value (US$ Mn) Forecast By Drug Class, 2014–2024
7.2.1. GLP-2
7.2.2. Growth Hormone
7.2.3. Glutamine
7.2.4. Others
7.3. Market Value (US$ Mn) Forecast By Country, 2014–2024
7.3.1. U.S.
7.3.2. Canada
7.3. Market Attractiveness Analysis
7.3.1. By Drug Class
7.3.2. By Country

8. Europe Short Bowel Syndrome Analysis and Forecast
8.1. Introduction
8.1.1. Key Findings
8.1.2. Key Trends
8.2. Market Value (US$ Mn) Forecast By Drug Class, 2014–2024
8.2.1. GLP-2
8.2.2. Growth Hormone
8.2.3. Glutamine
8.2.4. Others
8.3. Market Value (US$ Mn) Forecast By Country, 2014–2024
8.3.1. U.K.
8.3.2. Germany
8.3.3. France
8.3.4. Italy
8.3.5. Spain
8.3.6. Rest of Europe
8.4. Market Attractiveness Analysis
8.4.1. By Drug Class
8.4.2. By Country

9. Rest of the World Short Bowel Syndrome Analysis and Forecast
9.1. Introduction
9.2. Market Value (US$ Mn) Forecast By Drug Class, 2014–2024
9.3. Regional Insights
9.3.1. Japan
9.3.2. India
9.3.3. Australia/New Zealand
9.3.4. China
9.3.5. Middle East
9.3.6. Brazil

10. Competition Landscape
10.1. Market Player – Competition Matrix (By Tier and Size of companies)
10.2. Market Share Analysis by Company (2015)
10.3. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
10.3.1. Ardelyx, Inc.
10.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
10.3.1.2. Business Overview
10.3.1.3. Product Portfolio
10.3.1.4. Financial Overview
10.3.1.5. SWOT Analysis
10.3.1.6. Strategic overview
10.3.2. Emmaus Life Sciences, Inc.
10.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
10.3.2.2. Business Overview
10.3.2.3. Product Portfolio
10.3.2.4. Financial Overview
10.3.2.5. SWOT Analysis
10.3.2.6. Strategic overview
10.3.3. GLyPharma Therapeutic, Inc.
10.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
10.3.3.2. Business Overview
10.3.3.3. Product Portfolio
10.3.3.4. Financial Overview
10.3.3.5. SWOT Analysis
10.3.3.6. Strategic overview
10.3.4. Merck KGaA
10.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
10.3.4.2. Business Overview
10.3.4.3. Product Portfolio
10.3.4.4. Financial Overview
10.3.4.5. SWOT Analysis
10.3.4.6. Strategic overview
10.3.5. Naia Pharmaceuticals, Inc.
10.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
10.3.5.2. Business Overview
10.3.5.3. Product Portfolio
10.3.5.4. Financial Overview
10.3.5.5. SWOT Analysis
10.3.5.6. Strategic overview
10.3.6. Nutrinia Ltd.
10.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
10.3.6.2. Business Overview
10.3.6.3. Product Portfolio
10.3.6.4. Financial Overview
10.3.6.5. SWOT Analysis
10.3.6.6. Strategic overview
10.3.7. OxThera
10.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
10.3.7.2. Business Overview
10.3.7.3. Product Portfolio
10.3.7.4. Financial Overview
10.3.7.5. SWOT Analysis
10.3.7.6. Strategic overview
10.3.8. Sancilio & Company, Inc.
10.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
10.3.8.2. Business Overview
10.3.8.3. Product Portfolio
10.3.8.4. Financial Overview
10.3.8.5. SWOT Analysis
10.3.8.6. Strategic overview
10.3.9. Shire plc
10.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
10.3.9.2. Business Overview
10.3.9.3. Product Portfolio
10.3.9.4. Financial Overview
10.3.9.5. SWOT Analysis
10.3.9.6. Strategic overview
10.3.10. Zealand Pharma A/S
10.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
10.3.10.2. Business Overview
10.3.10.3. Product Portfolio
10.3.10.4. Financial Overview
10.3.10.5. SWOT Analysis
10.3.10.6. Strategic overview

List of Figures

Figure 01: Global Short Bowel Syndrome Size (US$ Mn) and Forecast, 2016–2024
Figure 02: Global Market Value Share, by Drug Class (2016)
Figure 03: Global Market Value Share, by Region (2016)
Figure 04: Causes of SBS in neonates in neonatal intensive care units (NICU)
Figure 05: Causes of SBS in adults
Figure 06: Global Short Bowel Syndrome Market Value Share Analysis, by Drug Class, 2015 and
Figure 07: Global GLP-2 Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 08: Global Growth Hormone Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 09: Global Glutamine Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 10: Global Others Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 11: Short Bowel Syndrome Market Attractiveness Analysis, by Drug Class
Figure 12: Global Short Bowel Syndrome Market Revenue, US$ Mn, 2014–2024
Figure 13: Global Short Bowel Syndrome Market Value Share Analysis, by Region, 2015 and 2024
Figure 14: Short Bowel Syndrome Market Attractiveness Analysis, by Region
Figure 15: North America Short Bowel Syndrome Market Size (US$ Mn) Forecast, 2014–2024
Figure 16: North America Market Attractiveness Analysis, by Drug Class
Figure 17: North America Market Attractiveness Analysis, by Country
Figure 18: North America Short Bowel Syndrome Market Value Share Analysis, by Drug Class, 2015 and 2024
Figure 19: North America Short Bowel Syndrome Market Value Share Analysis, by Country, 2015 and 2024
Figure 20: Europe Short Bowel Syndrome Market Size (US$ Mn) Forecast, 2014–2024
Figure 21: Europe Market Attractiveness Analysis, by Drug Class
Figure 22: Europe Market Attractiveness Analysis, by Country
Figure 23: Europe Short Bowel Syndrome Market Value Share Analysis, by Drug Class, 2015 and 2024
Figure 24: Europe Short Bowel Syndrome Market Value Share Analysis, by Country, 2015 and 2024
Figure 25: Rest of the World Short Bowel Syndrome Market Size (US$ Mn) Forecast, 2014–2024
Figure 26: Global Short Bowel Syndrome Market Share Analysis, by Company (2015)

List of Tables

Table 01: Overview of clinical trials for short bowel syndrome
Table 02: Global Short Bowel Syndrome Market Size (US$ Mn) Forecast, by Drug Class, 2014–2024
Table 03: Global Short Bowel Syndrome Market Size (US$ Mn) Forecast, by Region, 2014–2024
Table 04: North America Short Bowel Syndrome Market Size (US$ Mn) Forecast, by Drug Class, 2014–2024
Table 05: North America Short Bowel Syndrome Market Size (US$ Mn) Forecast, by Country, 2014–2024
Table 06: Europe Short Bowel Syndrome Market Size (US$ Mn) Forecast, by Drug Class, 2014–2024
Table 07: Europe Short Bowel Syndrome Market Size (US$ Mn) Forecast, by Country, 2014–2024

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界の短期腸症候群市場(医薬品クラス- GLP-2、成長ホルモン、グルタミン)-グローバル産業分析、規模、シェア、量、成長、動向及び予測2016-2024(Short Bowel Syndrome Market (Drug Class - GLP-2, Growth Hormone, and Glutamine) - Global Industry Analysis, Size, Share, Volume, Growth, Trends, and Forecast 2016 - 2024)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆